News

A conversation with David S. Friedman, MD, PhD, on treating uncontrolled open-angle glaucoma in patients with limited options

Following his keynote address at Controversies in Modern Eye Care, Dr. Maloney said he will be leaving his surgical practice and returning to research.

The investigators described the CASIA2 (Tomey Corporation) instrument, which is a new AS-OCT device with a swept-source laser wavelength of 1,310 nm that can scan at a speed of 50,000 A-scan/second.

The new surgical technique incorporates a new surgical clamp that maintains eye pressure during the insertion of 2 tissue patches in immediate succession while minimizing damage to the surrounding tissue.

A significant proportion of cataract surgery patients exhibit hyperosmolar tear film both before and 1 month after surgery, underscoring preoperative screening and postoperative management to optimize visual outcomes.

ABCA4-associated retinopathies include Stargardt disease, retinitis pigmentosa 19, and cone-rod dystrophy 3.

According to the company, results showed “a meaningful clinical improvement in ocular surface health” and significance for both staining end points at day 15.

At ARVO 2025, in Salt Lake City, Utah, Steven Barnes, PhD, talked about his research on the OPA1 mutation in retinal ganglion cells' effect on the cell's electrical function.

Ayres shares insights on using a trocar-free, 27-gauge vitrector to improve surgeon comfort and patient safety in anterior vitrectomy

Swedish researchers reveal that vitamins B6, B9, B12, and choline offer neuroprotection against glaucoma, highlighting potential new treatment avenues.

At ARVO 2025, in Salt Lake City, Utah, Hsin-Yu Yang talked about the 9-month results from her study on the effectiveness of DIMS spectral lenses in myopic retardation for the pre-myopic preschoolers in Taiwan.

In this Q&A, John D. Gelles, OD, and Steven Greenstein, MD, chat about what inspired them to launch the symposium, what makes this year’s agenda especially exciting, and why the future of refractive care depends on stronger collaboration between ODs and MDs.

At ARVO 2025, in Salt Lake City, Utah, Alex Choi discussed his poster on APOE carrier genetic status and its relation to Alzheimer disease as well as changes of the retina that might reflect early signs leading to an earlier diagnosis of the disease

Steven Greenstein, MD, one of the cochairs of the Collaborative Care Symposium gave some insight into the upcoming conference and what attendees can expect.

At ARVO 2025, in Salt Lake City, Utah, Yuhua Zhang, PhD, talked about his presentation on in vivo imaging of retinal pigment epithelium metabolic function in age-related macular degeneration

At ARVO 2025, in Salt Lake City, Utah, Patipol Tiyajamorn, talked about his poster on using graph neural networks to identify fast glaucoma progressors solely using optic nerve head morphology at a single time point

At ARVO 2025, in Salt Lake City, Utah, Anisha Kasi talked about her presentation on how her team used the TriNetX database, a large database of over 150 million patients worldwide, to validate the connection between hidradenitis suppurativa and inflammatory eye conditions.

At ARVO 2025, in Salt Lake City, Utah, Xiaolin Wang, MS, talked about her presentation on in vivo imaging of retinal pigment epithelium metabolic function in AMD.

Susvimo is the first and only FDA-approved, continuous delivery treatment shown to maintain vision in people with DR with just one refill every 9 months

Join global experts at the 2025 International SPECTRALIS Symposium in Heidelberg, exploring innovations in ophthalmology and space-related ocular health.

At ARVO 2025, in Salt Lake City, Utah, Noemi Guemes-Villahoz, MD, PhD, talked about 12-month results of vision-related quality of life in myopic children using combination treatment with atropine and DIMS (Defocus Incorporated Multiple Segments) spectacle lenses.

New research links diffuse-trickling patterns in fundus autofluorescence to increased ellipsoidal zone loss, highlighting potential biomarkers for rapid geographic atrophy progression.

Matthew Starr, MD, highlights the RHONE-X trial's findings on faricimab, showcasing improved vision and reduced treatment burden for diabetic macular edema patients.

At ARVO 2025, in Salt Lake City, Utah, Peng Shang, PhD, talked about her presentation on how the Y402H polymorphism of Complement Factor H (CFH), a major genetic risk factor for AMD, and chronic oxidative stress affect the lipid profile of retinal pigment epithelial (RPE) cells.

The designation is based off previously reported phase 3 data from the ongoing DRAGON trial.